Samsung Bioepis Reports Real-World Data of Benepali (biosimilar, etanercept) in Patients with Psoriasis at EADV 2019

C-Bridge Capital Signs a Development & Commercialization Agreement with Samsung Bioepis for Biosimilars in China


  • The study enrolled BADBIR-registered patient treated with Benepali from Jan 01, 2016 to Sept 01, 2018. BADBIR is a UK and Ireland observational study assessing long-term safety of biologic treatments for psoriasis while Samsung Bioepis participated in it since May 2016
  • The mean disease duration was 22.6 yrs., PASI and DLQI scores 11.6 and 13.1 respectively, median treatment period 14.1 months. In 48 patients with PASI score at baseline and 6 mos. PASI < 10 (N=20, mean PASI 3.2) no increment after 6 mos. and PASI ≥ 10 (N=28, mean PASI 15.7) reduced after 6 mos. (mean PASI 5.0)
  • Benepali (biosimilar, etanercept) referencing Enbrel is an anti-TNF biosimilar approved by EC in Jan 2016, for moderate to severe RA, JIA, PsA, axSpA  (ankylosing spondylitis and non-radiographic axial spondyloarthritis), and plaque psoriasis and is available in 25 countries in EU plus most prescribed across France, Germany, Italy, Spain, and the UK combined

Click here to­ read full press release/ article | Ref: Samsung Bioepis | Image: Twitter